Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551392 | 0.80 | HTT (0.52) | CYP1A2CYP2C19HTTKDM4EMAPT | |
| SCHEMBL4470656 | 0.80 | HTT (0.52) | CYP1A2CYP2C19HTTKDM4EMAPT | |
| SCHEMBL3969039 | 0.80 | ALDH1A1 (0.52) | CYP1A2CCR1CCR8KDM4EMAPT | |
| SCHEMBL17838975 | 0.78 | SYK (0.46) | CYP1A2CYP2C19HTTKDM4EMAPT | |
| SCHEMBL18515670 | 0.77 | CCR1 (0.46) | CYP1A2HTTCCR1CCR8KDM4E | |
| SCHEMBL15765873 | 0.77 | NR4A2 (0.62) | CYP1A2CCR1CCR8KDM4EMAPT | |
| SCHEMBL19001719 | 0.77 | CCR1 (0.46) | CYP1A2HTTCCR1CCR8KDM4E | |
| SCHEMBL5542655 | 0.77 | CYP1A2 (0.47) | CYP1A2HTTCCR1CCR8KDM4E | |
| SCHEMBL5542662 | 0.77 | ALDH1A1 (0.48) | CYP1A2HTTCCR1CCR8KDM4E | |
| SCHEMBL14659006 | 0.77 | HTT (0.48) | CYP1A2CYP2C19HTTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2019-05-23 | — | — | US | disclosed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | CYP1A2 128/4885CYP2C19 227/4885HTT 3733/4885 |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | CYP1A2 128/4885CYP2C19 227/4885HTT 3733/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | CYP1A2 128/4885CYP2C19 227/4885HTT 3733/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | CYP1A2 128/4885CYP2C19 227/4885HTT 3733/4885 |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | CYP1A2 128/4885CYP2C19 227/4885HTT 3733/4885 |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | PKM, PDK1, PDK2 | CYP1A2 3978/4885CYP2C19 3253/4885HTT 1637/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | CYP1A2 2128/4885CYP2C19 1878/4885HTT 3966/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | CYP1A2 128/4885CYP2C19 227/4885HTT 3733/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | CYP1A2 128/4885CYP2C19 227/4885HTT 3733/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | CYP1A2 132/4885CYP2C19 239/4885HTT 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.